Pharmafile Logo

Omthera Pharmaceuticals

- PMLiVE

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

AZ says UK investments on hold until there is Brexit ‘clarity’

Tomorrow's EU summit could be make-or-break for Brexit deal

- PMLiVE

AstraZeneca: building a new ‘open innovation’ pharma company

The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects

- PMLiVE

Biopharma’s Future: Made in China

The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise

- PMLiVE

Imfinzi aces survival challenge in lung cancer

Earlier treatment leads to much extended lives, data suggests

- PMLiVE

AstraZeneca chief on Brexit: “It’s going to be really painful”

Soriot also claims to be lowest paid CEO in sector

- PMLiVE

AZ prepares to file COPD triple, taking on rival GSK

Latest salvo in combination trials competition

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

AstraZeneca AZ

AstraZeneca joins Merck in Brexit stockpiling effort

Says it is increasing stores of medicines by around 20%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links